查看文章

We appreciate Dr. Öner Özdemir’s thoughtful letter in response to our article “COVID-19 in Children with Asthma”[1]. We absolutely agree it is necessary to conduct large-scale epidemiologic studies, clinical trials, and mechanistic studies to disentangle the risk or protective factors for modulating the susceptibility of children with asthma to SARS-CoV-2 infection.

With regard to misconceptions, the author writes that our claims about the potential mechanisms of the mild course of COVID-19 in children obfuscate the multisystem inflammatory syndrome (MIS-C). Recent studies reveal that the majority of children with COVID-19 either remain asymptomatic or present with mild symptomatology [2]. Data from large epidemiological studies showed that only 1%–2% of the recorded SARS-CoV-2 cases [3–5] and less than 1% of hospital admissions [3–7] involved children. A systemic review from 26 countries reported an …